

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01.

Regulation FD Disclosure.

On November 21, 2016, International Isotopes Inc. (the Company) issued a press release announcing that the Company submitted an abbreviated new drug application to the U.S. Food and Drug Administration for its *I¹³¹odine/MAXTM* sodium iodide radiopharmaceutical product. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.

Financial Statements and Exhibits.

(d) *Exhibits.*

Exhibit

No.	Description
99.1	Press release dated November 21, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 21, 2016

International Isotopes Inc.

By:

/s/ Steve T. Laflin
Steve T. Laflin

President and Chief Executive Officer

EXHIBIT INDEX

Exhibit

No.	Description
99.1	Press release dated November 21, 2016.